<DOC>
	<DOCNO>NCT00937027</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetic property ( absorption , distribution excretion ) two preparation aminopterin ( 0.25 mg tablet 1.0 mg tablet ) follow oral administration subject moderate severe psoriasis .</brief_summary>
	<brief_title>Aminopterin Pharmacokinetic Study In Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>Give write informed consent sign IRBapproved Informed Consent . Be treatment least moderate severe psoriasis ( diagnosis confirm dermatologist ) MTX ( 1020 mg per week ) minimum 3 month . Moderate severe psoriasis define plaquetype psoriasis affect body surface area &gt; 10 % . Be 21 year age old , 60 year age old . If participant female child bear potential , subject must indicate pregnant . Must fully inform potential AMT adversely affect fetus , must agree use highly effective method birth control begin time consent , study , 3 month leave study . Women childbearing potential may enter study confirm menstrual period , must negative urine pregnancy test time screen within 24 hour study drug dose . Have adequate hematologic function evidence follow : result obtain blood sample drawn within 2 day day 0 : WBC &gt; 4,500/ mm3 Platelet Count &gt; 150,000/mm3 Hemoglobin &gt; 12.0 gm/dL Have adequate liver function evidence follow result obtain blood sample drawn within 2 day day 0 : AST ( SGOT ) ≤ 40 IU/L ALT ( SGPT ) ≤ 40 IU/L Alkaline Phosphatase ≤ 120 IU/L Total Bilirubin ≤ 1.2 mg/dL Have adequate renal function evidence follow result obtain blood sample drawn within 2 day day 0 : GFR estimate CockcroftGault formula : &gt; 90 ml/min ( male ) &gt; 90 ml/min ( female ) Have detectable urine glucose , urine ketone , urine protein sample obtain within 2 day day 0 . Weight 35 90 kg . A known history hepatitis , liver fibrosis cirrhosis ( grades IIIA , IIIB IV ) , diabetes ( type I II ) , HIV infection , tuberculosis , interstitial lung disease , abnormal screen chest xray consistent interstitial lung disease . Known peptic ulcer , ulcerative colitis Crohn 's disease . Body mass index ( BMI ) &lt; 19.0 &gt; 35.0 ( see appendix C ) . Within 2 week prior randomization use follow medication may result drug/drug interaction aminopterin : methotrexate , trimethoprim without sulfamethoxazole ; sulfonamide ; sulfonylurea ; pyrimethamine ; triamethamine ; dipyridamole ; colchicine ; probenecid ; aminoglycosides ; theophylline ; phenytoin ; folinic acid ( i.e. , leucovorin ) unless prescribe investigator treat study drug relate toxicity . Within 2 week prior randomization use salicylate , nonsteroidal antiinflammatory ( NSAID ) drug , include OverTheCounter nonprescription use aspirin , ibuprofen naproxen . Use medication may negatively influence regular folic acid supplementation antiepileptic phenobarbital , diphenylhydantoin , primidone . Use investigational medication within 30 day prior admission study . Inability abstain alcohol study . A history substance abuse , drug addiction alcoholism . Unwillingness use adequate form contraception study 3 month study . A female pregnant , intend become pregnant study ( within 6 month study completion ) , nurse . Concurrent participation another clinical trial involve experimental treatment . Current uncontrolled infection , cardiovascular , pulmonary , hepatic GI condition interfere conduct trial pose additional morbid risk . Any renal condition interfere conduct trial pose additional morbid risk . Any concurrent disease condition opinion investigator impair subject 's ability complete trial . Psychological , familial , sociological , geographical medical condition , Investigator 's opinion , could compromise compliance objective procedure protocol obscure interpretation trial 's data .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Antifolate</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Antiinflammatory drug</keyword>
	<keyword>Autoimmune disease</keyword>
	<keyword>Treatment</keyword>
</DOC>